Drug Trial Radar · NCT05552976
A Study to Evaluate Mezigdomide in Combination With Carfilzomib and Dexamethasone (MeziKD) Versus Carfilzomib and Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma (SUCCESSOR-2)
Last checked: Nov 19, 2026Latest source record: Sep 24, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
606
Actual
Start
Jan 10, 2023
Primary completion
Sep 28, 2026
Study completion Jul 25, 2029
Sponsor
- Lead sponsor
- Bristol-Myers SquibbBristol Myers Squibb (BMY)
- Sponsor type
- Industry
- First posted
- Sep 23, 2022
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of the study is to compare Mezigdomide (CC-92480/BMS-986348) with carfilzomib and dexamethasone (MeziKD) against carfilzomib and dexamethasone (Kd) in the treatment of RRMM: SUCCESSOR-2.
Conditions
- Relapsed or Refractory Multiple Myeloma
Interventions
MezigdomideDrug
Specified dose on specified days
CarfilzomibDrug
Specified dose on specified days
DexamethasoneDrug
Specified dose on specified days
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Up to approximately 5 years
Locations
204 sites in 27 countries. Site status is shown where the registry gives one.
Local Institution - 0046
Mobile, Alabama
Local Institution - 0005
Cerritos, California
Local Institution - 0190
Irvine, California
Local Institution - 0187
Los Angeles, California
Local Institution - 0344
Santa Rosa, California
Local Institution - 0339
Stockton, California
Local Institution - 0341
Fort Myers, Florida
Local Institution - 0342
St. Petersburg, Florida
Local Institution - 0340
West Palm Beach, Florida
Local Institution - 0348
Atlanta, Georgia
Local Institution - 0291
Atlanta, Georgia
Saint Alphonsus Regional Medical Center
Boise, Idaho
Local Institution - 0289
Annapolis, Maryland
Local Institution - 0204
Boston, Massachusetts
Local Institution - 0346
Minneapolis, Minnesota
Local Institution - 0222
Little Silver, New Jersey
Local Institution - 0199
The Bronx, New York
Local Institution - 0322
Cleveland, Ohio
Local Institution - 0172
Columbus, Ohio
Local Institution - 0321
Providence, Rhode Island
Local Institution - 0338
Greer, South Carolina
Local Institution - 0349
Chattanooga, Tennessee
Local Institution - 0323
Nashville, Tennessee
Local Institution - 0337
Fort Worth, Texas
Local Institution - 0328
Houston, Texas
Local Institution - 0044
Houston, Texas
Local Institution - 0195
Temple, Texas
Local Institution - 0345
Norfolk, Virginia
Local Institution - 0343
Roanoke, Virginia
Local Institution - 0006
Tacoma, Washington
Local Institution - 0347
Vancouver, Washington
Local Institution - 0243
Morgantown, West Virginia
Local Institution - 0336
Marshfield, Wisconsin
Local Institution - 0150
Buenos Aires, Argentina
Local Institution - 0151
Córdoba, Argentina
Local Institution - 0008
Ciudad Autónoma de Buenos Aires, Buenos Aires, Argentina
Local Institution - 0079
ABB, Buenos Aires F.D., Argentina
Local Institution - 0182
Rosario, Santa Fe Province, Argentina
Local Institution - 0319
San Miguel de Tucumán, Tucumán Province, Argentina
Local Institution - 0077
Camperdown, New South Wales, Australia
Showing 40 of 204 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.